About this trial
The clinical study investigates the long-term course of disease in patients with chronic inflammatory skin diseases (atopic eczema and psoriasis) and the impact of tarheted therapies on the clinical and molecular level. For this purpose, patients are asked to take part in regular examinations and data collections, and to donate biomaterials (blood, skin biopsies, skin swabs, tape strips, stool samples). Blood samples are used to analyze inflammation messengers. Punch biopsies from lesional and non-lesional skin areas are used to analyze gene expression. Tape strips are pieces of transparent adhesive tapes to strip off most of the horny layer that will be used to examine mRNA and protein expression. The skin smears are superficial smears of three areas of skin with cotton swabs, which are used to examine bacteria on the skin. Overall, the study will help to monitor the disease course clinically and on the molecular level in participating patients for at least ten years and to collect information about the impact of various external factors including treatments. The study has no effect on the therapies of the disease, it serves only the accompanying data collection
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients with a clinical diagnosis of atopic dermatitis, psoriasis or autoimmune skin disease
Written informed consent obtained from the subject
Disqualifiers
Patients who decline participation
Trial population
Patient who are beeing treated in the routine care with chronic inflammatory skin diseases will be asked to participate in this project.
Trial design
Case-control
Prospective
Treatments tested in this trial
Biosampling for molecular analysis
Other interventionObservational study with no therapeutic intervention. Biosampling for molecular analysis
Treatment groups
Trial outcomes
Primary outcomes
Disease progression
Epidemiological and phenotypical data of patients
Molecular signature changes
Molecular signatures will be measured using OMICS and sequencing technologies
Secondary outcomes
Development of comorbidities
Assessment of newly developed comorbid diseases over time
Sponsors and contacts
Click on the lead sponsor to view all of their trials.